Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Recent News

SITC 2022: Cellular Research May Lead to the Next Generation of Therapies for Myeloma
Should Routine Stem Cell Transplantation Be Discontinued in Newly Diagnosed Patients With Myeloma?
SITC 2022: Antigen-Specific Memory CD8-Positive T Cells Target BCMA to Treat Multiple Myeloma
ASTRO 2022: CNS-Directed Radiotherapy for Patients With Extramedullary Multiple Myeloma
ASTRO 2022: Can Radiotherapy Prevent Progression to Myeloma in Patients With Plasmacytomas?
FDA Brief: Bispecific Antibody Receives Breakthrough Therapy Designation in Resistant Myeloma
SLAMF7 Antigen and Myeloma: Therapeutic Target for Antibody-Based and Cellular Immunotherapy?
Daratumumab-Based Chemoimmunotherapy for Multiple Myeloma: Focus on Advanced Renal Failure
ASTRO 2022: Community-Based Registry Offers Glimpse at Use of Radiotherapy for Myeloma
FDA Brief: Teclistamab-cqyv Granted Accelerated Approval in Resistant Myeloma
CD38-CAR Natural Killer Cells: Potential Immunotherapy Target in Multiple Myeloma?
SOHO 2022: Exploring the Role of Salvage Autologous HCT in Myeloma
Gut Microbiota and Gastrointestinal Toxicity From Proteasome Inhibitors in Myeloma
Early-Phase Research on Sotatercept in Combination Therapy for Resistant Multiple Myeloma
SOHO 2022: Update From CARTITUDE-2 of Ciltacabtagene Autoleucel in Multiple Myeloma
Can a Mutational Signature Predict Outcomes With Carfilzomib-Based Therapy for Myeloma?
ASCO Quality 2022: Underrepresentation of Black Patients in Multiple Myeloma Clinical Trials
BCMA-Targeted CAR T-Cell Therapy for Older Patients With Multiple Myeloma
Are Baseline Ocular Conditions Affected by Belantamab Mafodotin Treatment in Myeloma?
Red Cell Distribution Width: A Prognostic Indicator in Newly Diagnosed Multiple Myeloma?
Novel PANGEA Models May Improve Clinical Prediction of Disease Progression to Myeloma
ODAC on Melphalan Flufenamide in Resistant Myeloma: Risk-Benefit Profile Not Favorable for Approved Indication
T-Cell Engagers and Antitumor Immunity in Multiple Myeloma Therapy
ESMO 2022: Wait Time for Diagnosis of Multiple Myeloma in the United States
ESMO 2022: BCMA-Specific CAR T-Cell Therapy Using a Synthetic Binding Domain in Multiple Myeloma
Patient-Reported Outcomes of Clinical Trial Participation Versus Standard Care for Multiple Myeloma
Infectious Complications Among Newly Diagnosed Patients With Myeloma in Latin America
4-Year Study Results With Novel Immunotherapy for Resistant Multiple Myeloma
Do Clinical Trials Match the Demographic and Geographic Diversity of Populations With Blood Cancers?
Quadruplet Therapy for Newly Diagnosed Multiple Myeloma: De-escalation Approach Under Study
Many Caregivers of Patients With Myeloma Struggle With Mental Health Challenges
A Global Evaluation of Multiple Myeloma: Incidence, Mortality, and Risk Factors
Researchers Find Circular RNA May Modulate the Progression of Multiple Myeloma
Triple-Class–Exposed Patients With Myeloma: Ciltacabtagene Autoleucel Versus Real-World Therapies
Follow-up on Elotuzumab-Based Regimen in High-Risk Multiple Myeloma
Teclistamab Plus Daratumumab Under Study in Resistant Multiple Myeloma
Phase II Trial of Daratumumab-Based Regimen in Multiple Myeloma
Novel CAR T-Cell Therapy for Resistant Myeloma in Early-Phase Study
Carfilzomib Plus Lenalidomide and Dexamethasone After ASCT for Multiple Myeloma
Study Update on Teclistamab in Resistant Multiple Myeloma
BCMA-Targeting CAR T-Cell Product for Relapsed or Refractory Multiple Myeloma
Daratumumab-Based Regimen as Salvage Therapy for Resistant Myeloma
ASCO 2022: Combination Therapy With Umbilical Cord Blood–Derived Natural Killer Cells for Myeloma
Can PET/CT Imaging Predict Survival in Multiple Myeloma Relapse?
ASCO 2022: Phase II MagnetisMM-3 Trial Focuses on Elranatamab in Resistant Myeloma
ASCO 2022: Update From Cohort A of CARTITUDE-2 on Ciltacabtagene Autoleucel in Myeloma
ASCO 2022: Ixazomib Plus Daratumumab in Elderly Frail Patients With Resistant Multiple Myeloma
ASCO 2022: Early-Phase Study of Talquetamab in Resistant Multiple Myeloma
ASCO 2022: Daratumumab-Based Therapy for High-Risk Smoldering Myeloma
ASCO 2022: Update From CARTITUDE-1 on Ciltacabtagene Autoleucel in Refractory Myeloma
ASCO 2022: Induction Triplet Regimen With or Without ASCT and Maintenance Therapy for Myeloma
Neuroepigenetic Changes and Their Influence on Bortezomib-Induced Peripheral Neuropathy


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.